| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 275.4 | 216.8 |
| Profit before tax | 16.9 | 24.3 |
| Net income | 15.2 | 24.3 |
| EPS (diluted, $ a share) | $0.05 | $0.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -37.3% |
|---|---|
| Revenue, year on year | +27.0% |
| Operating margin | 7.0% |
10-Q filed with the SEC, NASDAQ: CAI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Caris Life Sciences, Inc.: key numbers
- Share price
- $21.00Close, Nov 16
- Market cap
- $6.02B
- Shares outstanding
- 286.78MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Caris Life Sciences, Inc.
All →Caris Life Sciences Earnings Call: Key Takeaways
Caris Life Sciences delivered record Q3 2026 revenue of $275.4M, up 27%, while raising full-year guidance and expanding its oncology platform into monitoring and MRD markets.
- Call
- Nov 4, 2026, 4:30 PM ET
Caris Life Sciences Financial Results
Caris Life Sciences reported Q3 2026 revenue of $275.4 million, a 27% increase year-over-year, driven by strong molecular profiling clinical case volume. The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion and reported positive net income of $15.3 million for the quarter.
- Term
- Q3 2026
“This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year. Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey.”
David Dean Halbert, Founder, Chairman and CEO
Caris Life Sciences Investor Presentation
Caris Life Sciences announced that its management team will use a formal investor presentation for meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference beginning September 14, 2026. The presentation will be made available on the company's investor relations website.
- Counterparty
- Morgan Stanley 24th Annual Global Healthcare Conference